Myogenic Akt signaling upregulates the utrophin–glycoprotein complex and promotes sarcolemma stability in muscular dystrophy by Peter, Angela K. et al.
Myogenic Akt signaling upregulates the utrophin–
glycoprotein complex and promotes sarcolemma
stability in muscular dystrophy
Angela K. Peter1,{, Christopher Y. Ko1,{, Michelle H. Kim1, Nigel Hsu1, Noriyuki Ouchi3, Suhn
Rhie1, Yasuhiro Izumiya3, Ling Zeng3, Kenneth Walsh3 and Rachelle H. Crosbie1,2, 
1Department of Physiological Science and
2Molecular Biology Institute, University of California, Los Angeles, CA
90095, USA and
3Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine,
Boston, MA 02118, USA
Received September 8, 2008; Revised and Accepted October 25, 2008
Duchenne muscular dystrophy is caused by dystrophin mutations that lead to structural instability of the sar-
colemma membrane, myoﬁber degeneration/regeneration and progressive muscle wasting. Here we show
that myogenic Akt signaling in mouse models of dystrophy promotes increased expression of utrophin,
which replaces the function of dystrophin thereby preventing sarcolemma damage and muscle wasting. In
contrast to previous suggestions that increased Akt in dystrophy was a secondary consequence of pathol-
ogy, our ﬁndings demonstrate a pivotal role for this signaling pathway such that modulation of Akt can sig-
niﬁcantly affect disease outcome by ampliﬁcation of existing, physiological compensatory mechanisms.
INTRODUCTION
Muscular dystrophy describes a group of genetic disorders
generally characterized by progressive muscle weakness.
The most common form of muscular dystrophy, Duchenne
muscular dystrophy (DMD), is caused by primary mutations
in the dystrophin gene (1–3). DMD is characterized by pro-
gressive muscle weakness eventually leading to cardiac and
respiratory failure. Dystrophin deﬁciency alters the stability
of the entire dystrophin-glycoprotein complex (DGC) result-
ing in reduction of the entire complex at the plasma membrane
(for review 4). In skeletal muscle ﬁbers, the core components
of the DGC include dystrophin, the dystroglycans (a- and
b-DG), the sarcoglycans (a-, b-, g- and d-SG), sarcospan
(SSPN) and the syntrophins (for review 5). Peripheral and
integral membrane components of the DGC provide a physical
connection between the extracellular matrix and the intracellu-
lar actin cytoskeleton (3,6–10). Loss of dystrophin and the
DGC alters the integrity of the sarcolemma, the skeletal
muscle plasma membrane, increasing contraction-induced
damage. Even though skeletal muscle possesses the innate
ability to regenerate, this ability is insufﬁcient to compensate
for the structural damage endured during muscle contraction
in DMD patients. Thus, the link between the extracellular
membrane and the intracellular cytoskeleton provided by the
DGC is essential for maintaining sarcolemmal stability.
The regenerative capacity of skeletal muscle is insufﬁcient
in combating persistent and widespread degeneration of myo-
ﬁbers with structural defects in the sarcolemma. Akt, a serine/
threonine protein kinase, has previously been shown to be
altered in both DMD patients and in dystrophin-deﬁcient
mdx mice (11,12). Previous reports indicate that activation
of the phosphatidylinositol 3-kinase (PI(3)K)/Akt pathway is
critical for the activation of muscle hypertrophy (13–17).
We and others have established that the same PI(3)K/Akt sig-
naling pathways responsible for inducing skeletal muscle
hypertrophy (13) are also activated in many forms of muscular
dystrophy (11,12). Furthermore, we have recently demon-
strated that direct manipulation of Akt in normal, wild-type
(WT) mice induces skeletal muscle hypertrophy that results
†These authors contributed equally to this work.
 To whom correspondence should be addressed at: Department of Physiological Science, University of California Los Angeles, 621 Charles E. Young
Drive South, Life Sciences Building Room 5804, Los Angeles, CA 90025, USA. Tel: þ1 3107942103; Fax: þ1 3102063987; Email: rcrosbie@physci.
ucla.edu
# 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 2 318–327
doi:10.1093/hmg/ddn358
Advance Access published on November 4, 2008in dramatic improvements in force generation while decreas-
ing adipose mass (18). Taken together, these previous
reports indicate activation of Akt in dystrophic muscle may
be a key mediator of the hypertrophic response both in the pro-
motion of muscle hypertrophy and in blood vessel recruitment.
The Akt family of protein kinases is activated by numerous
extracellular stimuli transduced across the membrane through
membrane-bound receptor tyrosine kinases (for review 20).
Akt is then recruited to the plasma membrane through acti-
vation of PI(3)K. Subsequent phosphorylation releases Akt
from the plasma membrane and leads to translocation of phos-
phorylated Akt (P-Akt) to the cytoplasm and activation of
downstream targets. Although recent research has reported
Akt translocation to the nucleus following activation (for
review 20), Akt remains in the cytosolic fraction following
activation in skeletal muscle (11). We have created a skeletal
muscle-speciﬁc, conditional transgenic mouse expressing a
constitutively active form of Akt (18). In this study, an
increase in Akt activation in skeletal muscle led to muscle
hypertrophy speciﬁcally in type IIb ﬁbers. The induction of
hypertrophy was also accompanied by increased ﬁber strength,
decreased fat mass and improvement of metabolic parameters
(18). These ﬁndings indicate that Akt activation alone can
increase muscle mass and improve muscle strength.
In the current report, we examined the effect of constitutive
Akt activation on the dystrophic pathology in dystrophin-
deﬁcient mdx mice. We demonstrate that activation of the
Akt transgene at the prenectroic (,3.5 weeks of age) stage
of disease delays the onset of dystrophic pathology in mdx
mice. We exploited the conditional transgene (18) to activate
the transgene for a total of 3 weeks before analyzing the tissue
for signs of muscular dystrophy. We show an increase in
muscle hypertrophy and decreased sarcolemmal fragility in
Akt-treated mdx mice compared with the untreated mdx con-
trols. The mechanism of amelioration involves increased
expression and wider distribution of adhesion complexes
including the utrophin–glycoprotein complex (UGC). Overex-
pression of the UGC has previously been shown to ameliorate
the dystrophic pathology in mdx mice (21,22). These ﬁndings
suggest that the overexpression and extra-synaptic localization
of the UGC and integrin compensate for the loss of the DGC in
Akt-transgenic, mdx mice. This current study identiﬁes myo-
genic Akt signaling as a drug target that could improve the
muscle wasting and sarcolemmal fragility associated with
muscular dystrophy by increasing expression of the UGC.
RESULTS AND DISCUSSION
Generation of mdx mice with inducible Akt1
expression in skeletal muscle
Toinvestigate whetherthebeneﬁcial effects of Aktwouldmani-
fest in dystrophic muscle, we engineered mice with muscular
dystrophy to express Akt1 by introducing the TRE-myrAkt1
and MCK-rtTA transgenes (18) into dystrophin-deﬁcient mdx
mice (Fig. 1). Offspring that had inherited only one of the TRE-
myrAkt1 or MCK-rtTA transgenes are referred to as single-
transgenic (STG) mice and lack the means for the conditional
activationofAkt1.Double-transgenic(DTG)offspringinherited
bothofthetransgenesandincreaseexpressionofAkt1upondox-
ycycline (DOX) treatment. All female offspring are heterozy-
gous for dystrophin (X
mdxX
WT) and display a non-dystrophic
phenotype, so they are referred to as WT mice. Male offspring,
described here as mdx mice, inherited only the deﬁcient copy of
dystrophin on the X chromosome (X
mdxY) and display a dys-
trophic phenotype without Akt activation. PCR analysis was
used to conﬁrm the six possible genotypes of transgenic off-
spring which are categorized into the following four groups:
WT STG, WT DTG, mdx STG and mdx DTG.
DOX-induced Akt overexpression causes muscle
hypertrophy in mdx mice
Similar to DMD patients, mdx mice possess a genetic mutation
in the dystrophin gene, resulting in loss of dystrophin protein
and the entire DGC (1–6). The peak necrotic stage of disease
occurs in mdx mice when they are between 3 and 6 weeks of
age and when the frequency of degeneration/regeneration is at
its greatest (23). In our model system, DOX, required for
transgene activation, was administered at the prenecrotic
Figure 1. Generation of Akt-transgenic mdx mice. Breeding scheme and
genotyping of offspring by PCR ampliﬁcation. Double-transgenic (TRE-
myrAkt1 þ MCK-rtTA) male mice on a wild-type (WT) dystrophin back-
ground were crossed with mdx females. Each transgenic offspring inherited
either one or both of the Akt transgenes (TRE-myrAkt1, MCK-rtTA). All
female offspring, which were heterozygous for dystrophin (X
mdx X
WT) and
expressing non-dystrophic phenotypes, are denoted as being either wild-type
single-transgenic (WT STG) or wild-type double-transgenic (WT DTG). All
male offspring possessed mdx genotypes (X
mdx Y) and are denoted as being
either mdx STG or mdx DTG. Transgenic offspring were genotyped through
two pairs of PCR ampliﬁcation reactions. In the ﬁrst pair of reactions, off-
spring were genotyped for the two transgenes responsible for the activation
of constitutively active Akt1. In the ﬁrst PCR reaction, the transgene for the
constitutively active form of Akt1 under the control of a tetracycline respon-
sive promoter (TRE-myrAkt1) is ampliﬁed, yielding a 380 bp product. In the
second PCR reaction, the transgene expressing a reverse tetracycline transac-
tivator under the control of a modiﬁed muscle creatine kinase promoter
(MCK-rtTA) was ampliﬁed, yielding a 567 bp product. In the second pair of
reactions, offspring were genotyped for the mdx locus. The forward primers
used in this pair of reactions are identical. In the ﬁrst reaction of the pair,
the WT allele was ampliﬁed using a WT allele-speciﬁc reverse primer. In
the second reaction, the mdx allele was ampliﬁed using an mdx allele-speciﬁc
reverse primer. Each reaction in this pair yielded a 275 bp product.
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(Fig. 2A). Increased Akt1 signaling induced obvious hind limb
hypertrophy and hypervascularization in mdx mice (Fig. 2B)
and increased quadriceps mass by 60% in WT (Fisher’s P ,
0.00001) and by 35% in mdx DTG mice (Fisher’s P , 0.005)
relative to their respective STG controls (Fig. 2C). Muscles
from both male and female mice displayed similar levels of
increased muscle mass upon transgene activation (Supplemen-
tary Material, Fig. S1). Immunoblotting skeletal muscle protein
lysates revealed comparable expression and functionality of the
Akt transgene in treated WT and mdx DTG mice. Detection of
exogenous Akt was facilitated by a hemagglutinin (HA) tag
engineered onto the TRE-myrAkt1 transgene. Induction of Akt
transgene was restricted to DTG muscle, while STG controls
with either the TRE-myrAkt1 or MCK-rtTA transgenes lacked
conditional Akt activation (Fig. 2D). The level of total Akt
protein overexpression in DTG muscle was increased by
2-fold relative to STG controls (Supplementary Material,
Fig. S2). DTG muscle also exhibited activation of p70
S6K and
MDM2 (Fig. 2D). p70
S6K is a downstream effector molecule
in the mammalian target of rapamycin (mTOR) pathway
which ampliﬁes protein translation and MDM2 functions in
part to enhance MyoD-controlled differentiation and transcrip-
tion (24).
We found that Akt activation increased cross-sectional
myoﬁber area in quadriceps muscle from both WT and mdx
DTG mice (Fig. 3A and B). The distribution of ﬁber cross-
sectional areas (CSAs) reveals increases in larger ﬁbers
(4500–7500 mm
2) for DTG mice (Fig. 3B). Central nuclea-
tion, a marker for ﬁber regeneration, was elevated in mdx
muscle (ANOVA, P , 0.005) and Akt activation in mdx
mice did not signiﬁcantly alter the frequency of central nuclea-
tion in mdx mice (Fig. 3C).
Improved sarcolemmal integrity upon Akt1
expression in mdx DTG mice
Loss of dystrophin and the DGC in mdx mice and in DMD
patients results in contraction-induced sarcolemmal disruption
and instability. Sarcolemmal integrity in mdx DTG mice was
Figure 2. Akt1 activation increases muscle mass in mdx mice. (A) Timeline of doxycycline (DOX) treatment of Akt STG and DTG mice. At three weeks of age,
the mice were treated with DOX, inducing Akt expression in Akt DTG mice for a total of three weeks. DOX treatment period corresponds to period of maximal
myoﬁber degeneration and regeneration in mdx mice. Tissues were analyzed at six weeks of age. (B) Representative images of mdx STG and mdx DTG mice
reveal dramatic differences in muscle mass. DTG mice display increased muscle mass (asterisk) and hypervascularization (arrow) after three weeks of transgene
activation. (C) Activation of Akt signiﬁcantly increases muscle mass in DTG mice. Induction of transgene in DTG mice signiﬁcantly increases total quadriceps
weight when compared to their WT (Fisher’s,  P , 0.00001) and mdx STG (Fisher’s,   P , 0.005) counterparts. Quadriceps weights are represented as an
average of the left and right quadriceps of each animal. Bars represent mean quadriceps weights (+SEM; n ¼ 21 mdx STG, n ¼ 4 mdx DTG. n ¼ 18 WT
STG, n ¼ 11 WT DTG). (D) Immunoblotting for Akt pathway proteins. Akt pathway proteins were detected from total skeletal muscle lysates of six-week-old
WT STG, WT DTG, mdx STG, and mdx DTG mice. Identical membranes were probed with antibodies against Akt, P-Akt, P-70S6K, P-GSK3b, P-MDM2, and
the HA-tag engineered onto the Akt1 transgene, as indicated. Coomassie blue staining of total protein is shown on the bottom panel (CB Stain) as a loading
control. Activation of Akt for three weeks is sufﬁcient for activation of P-70S6K in the Akt signaling axis. Furthermore, P-MDM2 levels increase upon Akt
activation whereas P-GSK3b levels remain constant.
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allows assessment of blood serum albumin inﬁltration into
damaged muscle ﬁbers. The quadriceps muscles of mdx STG
mice displayed elevated levels of EBD inﬁltration compared
with WT STG and DTG controls (Fig. 4A) due to the sarco-
lemmal fragility in mdx muscle. In contrast, Akt induction
ameliorated sarcolemmal damage in mdx DTG mice to
nearly WT DTG control levels (Fig. 4B; Student’s t-test
with Bonferroni adjustment, P , 0.03).
Akt activates muscle regeneration
The observation that central nucleation was unaffected in mdx
DTG mice suggested that myoﬁbers were undergoing regener-
ation despite restoration of membrane stability. Based on pre-
vious observations that Akt is involved in proliferation of
satellite cells (25), we postulated that regeneration in mdx
DTG muscle resulted from activation of satellite cells in Akt
over-expressing muscle. In order to test this observation, we
determined the myoﬁber CSA for WT DTG muscle after 2,
4 and 6 weeks of Akt1 transgene activation. For these
studies, we chose to induce Akt activation in adult WT mice
to avoid any complications of disease pathology that occur
in mdx muscles (i.e. diaphragm, soleus, cardiac and EDL
muscles do not express the Akt1 transgene) in this model
(18). Myoﬁber CSA doubled after 2 weeks of Akt1 activation
(Fig. 5A and B). An additional 2 weeks of Akt1 transgene acti-
vation increased the CSA by an additional 0.5-fold and no
further changes in myoﬁber size were detected after 6 weeks
of transgene overexpression (Fig. 5B). We found that the
levels of central nucleation were not affected by 2 weeks of
transgene activation nor were the number of nuclei per ﬁber
changed at this time point. Interestingly, central nucleation in
WT DTG muscle increased to over 20% after 4 and 6 weeks
of DOX treatment (Fig. 5C), which correlated with an increase
in the number of nuclei per CSA (Fig. 5D). Taken together, this
data suggests that Akt1 expression in muscle activates normally
quiescent satellite cells, which is further supported by the obser-
vation of elevated levels of mRNA transcripts for many satellite
cell markers (myoD, pax7, PCNA, myf6 and myogenin) in WT
DTG muscle (Table 1; data not shown).
Akt1 increases levels of several compensatory
adhesion complexes
To determine the mechanism of rescue for sarcolemma fragi-
lity in DTG mdx mice, we investigated expression of several
adhesion complexes that are known to rescue dystrophin
deﬁciency and restore membrane stability (1–6,16). We
found that induction of Akt signaling in mdx muscle increased
protein expression of the sarcoglycan and dystroglycan sub-
units to WT levels (Fig. 6). Akt activation increased utrophin
protein levels by a minimum of 5- and 10-fold, respectively, in
WT and mdx DTG muscle, relative to their STG controls
Figure 3. Akt1 activation increases ﬁber hypertrophy. (A) Transverse quadriceps muscle sections from six-week-old WT STG, WT DTG, mdx STG, and mdx
DTG mice were stained with hematoxylin and eosin (H&E) to visualize muscle histology. Constitutive Akt activation in mdx DTG mice did not reduce the
prevalence of centrally nucleated ﬁbers and necrosis when compared to non-phenotypic littermates. Note the muscle ﬁber hypertrophy in both groups of
DTG mice. Bar, 50 mm. (B) Distribution of cross sectional ﬁber areas of quadriceps muscle. DTG mice exhibit greater populations of both smaller and hyper-
trophic ﬁbers compared to their WT and mdx STG controls. (C) Central nucleation (% of total ﬁbers) in quadriceps muscle sections was quantiﬁed in each group
of mice. Mdx mice exhibit signiﬁcantly higher levels of central nucleation when compared to WT mice ( ANOVA, P , 0.005). However, DTG mice do not
exhibit signiﬁcant differences in the amount of central nucleation when compared to their STG control littermates. Central nucleation is represented as an
average of the % of central nucleation of the left and right quadriceps of each animal. Bars represent mean central nucleation. (n ¼ 3 WT STG, n ¼ 2W T
DTG, n ¼ 2 mdx STG, n ¼ 3 mdx DTG.).
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replaces dystrophin at the post-synaptic face of the neuromus-
cular junction to form the UGC (21). In addition to utrophin
up-regulation, dystrophin expression is up-regulated by
4-fold in WT DTG muscle thereby increasing overall levels
of both DGC and UGC (Fig. 6). Similar to utrophin, integrin
a7b1D is up-regulated in a compensatory fashion in mdx
mice (26) and Akt transgene induction increased integrin
b1D levels by 3-fold in mdx DTG muscle relative to STG
controls (Fig. 6). Dysferlin, which mediates membrane
repair in a calcium-dependent manner (27), was also increased
in both DTG models (Fig. 6).
Immunohistochemical analyses revealed that the UGC and
integrin b1D, which are normally restricted to the neuromus-
cular junction, are broadly localized throughout the extrasy-
naptic sarcolemma upon Akt expression (Fig. 7). Like
utrophin, the skeletal muscle-speciﬁc b1D isoform of integrin
is enriched at the neuromuscular and myotendinous junctions
in WT mice, but has been found to be up-regulated in mdx
mice (26). Overexpression of a7b1 integrin promotes
muscle hypertrophy and regeneration in mdx/utr
2/2 mice
(28). We found integrin b1 expression homogenously at the
sarcolemma in DTG skeletal muscle (Fig. 7).
To further assess the regulation of compensatory com-
plexes, quantitative real-time PCR was performed from skel-
etal muscle of STG and DTG mice. mRNA levels of several
genes including b-DG, a7 integrin, dysferlin and MyoD
were signiﬁcantly elevated in DTG muscle relative to STG
controls (Table 1). The observation that mRNA levels of the
muscle-speciﬁc transcription factor MyoD were tripled in
mdx DTG muscle supports a role for transcriptional regulation
of gene expression upon Akt1 activation. Akt1 regulates skel-
etal muscle differentiation, at least in part, by enhancing tran-
scriptional activity of MyoD via co-activators p300 and P/
CAF (29). In turn, MyoD controls transcription of genes
expressed during differentiation including a7 integrin, and
several components of the DGC and the UGC (30).
Here we demonstrate that myogenic expression of Akt1 in
dystrophin-deﬁcient muscle ameliorates crucial pathologies
of muscular dystrophy. Our studies suggest that Akt
up-regulates utrophin expression to levels that are sufﬁcient
to stabilize the sarcolemma in the absence of dystrophin and
thus ameliorate muscular dystrophy. These ﬁndings provide
a rationale for identiﬁcation of mechanisms to increase utro-
phin protein stability or translation as a means to increase utro-
phin protein expression, in addition to current strategies to
identify methods of augmenting utrophin transcription. We
demonstrate for the ﬁrst time that overexpression of a signal-
ing molecule that has been suggested to control hypertrophy
(13–17) can diminish the progressive muscle wasting associ-
ated with dystrophin deﬁciency. Akt may represent a critical
‘master switch’ for myoﬁber regeneration and modulation of
these pathways may have therapeutic value for a broad-range
of inherited and acquired muscle wasting disorders.
MATERIALS AND METHODS
Animal models
Mdx female retired breeders were purchased from Jackson
Laboratories (Bar Harbor, Maine). DTG mice which were pro-
duced by crossing 1256 [3Emut] MCK-rtTA transgenic mice
expressing the tetracycline transactivator controlled by a
mutated skeletal muscle creatine kinase promoter with TRE-
myrAkt1 transgenic mice harboring the constitutively active
form of the mouse Akt1 transgene controlled by a tetra-
cycline-responsive promoter. Male DTG mice were bred
with mdx females to produce four groups of mice used for
comparison: (i) Akt STG (either MCK-rtTA or TRE-myrAkt1)
females on an mdx heterozygous background, (ii) Akt DTG
females on an mdx heterozygous background, (iii) Akt STG
(either MCK-rtTA or TRE-myrAkt1) mdx males and (iv) Akt
Figure 4. Akt1 activation ameliorates sarcolemmal stability in mdx DTG
mice. (A) Detection of blood serum protein inﬁltration with Evans Blue dye
(EBD) tracer assay. Transverse sections of quadriceps muscle ﬁbers with
damaged sarcolemma are shown with red ﬂuorescence. Laminin in the base-
ment membrane is shown with green ﬂuorescence to delineate each myoﬁber.
EBD inﬁltration was absent in WT STG, detected in low levels in WT DTG
and mdx DTG mice, and elevated in mdx STG mice. Bar, 50 mm. (B) Quanti-
ﬁcation of EBD-positive ﬁbers in whole transverse quadriceps sections. Bars
represent percentage of EBD inﬁltrated ﬁbers in a whole quadriceps section
(+SEM; Student’s t-test with Bonferroni adjustment (a ¼ 0.025), N.S. WT
STG versus WT DTG,  P , 0.02, mdx DTG versus mdx STG; n ¼ 3 mice).
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mice, three-week-old mice were treated with DOX adminis-
tered in drinking water (0.5 mg/ml) for a three week period.
STG mice (TRE-myrAkt1 or MCK-rtTA) treated with DOX
were utilized as controls to eliminate any effect directly
related to DOX treatment. After DOX treatment, quadriceps
muscles and total skeletal muscles were harvested, weighed
and snap-frozen in liquid nitrogen or mounted in 10.2% poly-
vinyl alcohol/4.3% polyethylene glycol and rapidly frozen in
liquid nitrogen-cooled isopentane. All tissues were stored
at 2808C until analyzed. Mice were housed in the Life
Sciences Vivarium. All procedures were carried in accordance
with guidelines set by the UCLA Institutional Animal Care
and Use Committee.
Genotyping of Akt-transgenic mdx mice
Akt genotyping. PCR ampliﬁcations for transgenes were
carried out as previously described (18). Brieﬂy, the TRE-
myrAkt1 transgene was ampliﬁed using the following
primers: Tet-Akt #1 (50-CTGGACTACTTGCACTCCGAGA
AG-30) and Tet-Akt #2 (50-CTGTGTAGGGTCCTTCTTGA
GCAG-30). The cycling conditions were 958C, 5 min; then
958C, 30 s and 688C, 30 s for 30 cycles, followed by 728C,
10 min. The reaction yielded a 380 bp product. PCR ampliﬁca-
tions of the MCK-rtTA transgene was ampliﬁed using the fol-
lowing primers: MCK-rtTA #1 (50-CATCTGCGGACTGGA
AAAACAAC-30) and MCK-rtTA #2 (50-GCATCGGTAAAC
ATCTGCTCAAAC-30). The cycling conditions were 958C,
5 min; then 948C, 30 s; 628C, 30 s and 728C, 1 min. for 30
Figure 5. Akt activates muscle regeneration (A) Adult WT DTG mice were treated with DOX for two, four and six weeks. Transverse gastrocnemius muscle
sections from treated WT DTG mice were stained with hematoxylin and eosin (H&E) to visualize muscle histology. Muscle sections taken from mice treated
with vehicle control is shown (control). Note that muscle ﬁber hypertrophy is evident after two weeks of DOX administration. Bar, 50 mm. (B) Cross-sectional
area (CSA) of transverse gastrocnemius WT muscle was quantiﬁed after two, four and six weeks of DOX treatment. Mean values (mm
2) are provided to illustrate
overall myoﬁber hypertrophy that is evident after two weeks of Akt1 transgene activation. Values from control, vehicle-treated muscle are shown. (C) Central
nucleation (% of total ﬁbers) in gastrocnemius muscle sections was quantiﬁed in each group of mice. Regeneration, denoted by the presence of myoﬁbers with
centrally placed nuclei, is evident in WT muscle after four weeks of Akt activation. This regeneration is occurring in the absence of muscle pathology or disease.
Central nucleation is represented as an average of the % of central nucleation. (D) Quantiﬁcation of the number of nuclei per myoﬁber is provided. No statistical
(N.S.) difference in nuclei per myoﬁber was observed after two weeks of DOX treatment. After four and six weeks of Akt activation, the number of nuclei/
myoﬁber increased by 50% relative to controls. In panels B-D, bars represent standard error of the mean (Fisher’s  P , 0.05; n ¼ 7).
Table 1. Akt1-transgene activation mediates changes in mRNA levels
Gene Relative mRNA levels
Wild-type mdx
STG DTG STG DTG
Utrophin 1.00+0.10 1.09+0.18 0.57+0.22 0.72+0.15
b-DG 1.00+0.16 1.41+0.17 0.61+0.10 0.91+0.09
g-SG 1.00+0.11 1.57+0.30 0.83+0.26 1.01+0.15
ltga-7 1.00+0.14 1.93+0.20 0.78+0.07 1.81+0.22
Dysf 1.00+0.14 2.17+0.25 0.96+0.11 1.86+0.52
MyoD 1.00+0.10 2.08+0.33 0.63+0.11 1.87+0.25
Relative mRNA expression levels of utrophin, b-DG, g-SG, integrin a7,
dysferlin (dysf), MyoD as measured by qRT–PCR. mRNA levels were
normalized to internal control gene 36B4 and values are represented
relative to WT STG controls. Results are presented as mean+SEM (n ¼
4). Values in italics are statistically signiﬁcant in comparisons for STG and
DTG control sets (Fisher’s, P , 0.05).
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567 bp product.
Mdx genotyping. The mdx point mutation was screened using a
modiﬁed version of an ampliﬁcation-resistant mutation system
(ARMS) assay (31). Two separate PCR reactions were per-
formed. The WT PCR ampliﬁes the WT dystrophin allele
using the following oligonucleotide primers: p260E
(50-GTCACTCAGATAGTTGAAGCCATTTAG-30) and
p306F (50-CATAGTTATTAATGCATAGATATTCAG-30).
The mdx PCR ampliﬁes the mdx allele using the following oli-
gonucleotide primers: p259E (50-GTCACTCAGATAGTT
GAAGCCATTTAA-30) and p306F (50-CATAGTTATTAAT
GCATAGATATTCAG-30). PCR cycling conditions for both
reactions were 958C, 4 min; then 958C, 1 min; 558C, 1 min
and 728C, 1 min for 34 cycles, followed by 728C, 10 min.
Each reaction yielded a 275 bp product. All PCR reactions uti-
lized the GoTaq DNA Polymerase kit (Promega, Madison, WI,
USA).
Protein preparation
Snap-frozen skeletal muscles were crushed with liquid nitro-
gen and a mortar and pestle. Ice-cold RIPA lysis buffer [1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid,
5m M N-ethylmaleimide, 50 mM sodium ﬂuoride, 2 mM
b-glycerophosphate, 1 mM sodium orthovanadate, 100 nM
okadaic acid, 5 nM microcystin LR and 20 mM Tris–HCl, pH
7.6) was utilized for homogenization. Immediately before
addition of crushed tissue, protease inhibitors (0.6 mg/ml pep-
statin A, 0.5 mg/ml aprotinin, 0.5 mg/ml leupeptin, 0.75 mM
benzamidine and 0.1 mM phenylmethylsulfonyl ﬂuoride)
were added to the lysis buffer. Homogenates were rocked
at 48C for 1 h. Clariﬁed lysates were obtained following
centrifugation at 15 000g for 15 min. Clariﬁed tissue
lysates were stored at 2808C until analyzed by immunoblot
analysis.
Figure 6. Akt increases expression of compensatory proteins in mdx mice.
Immunoblotting for several glycoprotein complexes (DGC, UGC, integrin)
on skeletal muscle lysates from six-week-old WT STG, WT DTG, mdx
STG, and mdx DTG mice. Identical membranes were probed with antibodies
against dystrophin (Dys), utrophin (Utrn), alpha- and beta-dystroglycan
(a-DG, b-DG), alpha-, beta- and gamma-sarcoglycan (a-SG, b-SG, g-SG),
b1D integrin and dysferlin (Dysf). GADPH immunoblotting and Coomassie
blue (CB) staining of total protein are shown on the bottom panels as a
loading controls. Constitutive Akt activation increased the expression of the
DGC and UGC in WT mice. Utrophin levels increased in mdx mice compared
to those of WT mice. Increased expression of b1D integrin and dysferlin was
observed upon Akt activation in both WT mice and in mdx mice. Figure 7. Broad sarcolemmal distribution of compensatory proteins upon Akt
activation. Immunohistochemical analyses on transverse quadriceps sections
in WT STG, WT DTG, mdx STG and mdx DTG mice. Sections were
stained with antibodies to dystrophin (Dys), utrophin (Utrn), b1D integrin,
alpha- and beta-dystroglycan (a-DG, b-DG), alpha-, beta- and gamma-
sarcoglycan (a-SG, b-SG, g-SG) and sarcospan (SSPN), and visualized
using indirect immunoﬂuorescence. Increased expression of the DGC and
UGC in WT mice was observed upon constitutive activation of Akt1. Akt acti-
vation increased expression of only the UGC in mdx mice. An increase in utro-
phin levels was observed in mdx mice relative to levels in WT mice. In both
WT mice and in mdx mice, Akt activation increased the expression of b1D
integrin. Bar, 50 mm.
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Protein concentrations of clariﬁed tissue lysates were deter-
mined using the DC Protein Assay (Bio-Rad). Equal concen-
trations of protein samples (60 mg) were resolved by 4–20%
gradient SDS–PAGE (Pierce, Rockford, IL, USA) and trans-
ferred to nitrocellulose membranes (Millipore Corp., Billerica,
MA, USA) for subsequent immunoblot experiments. Primary
antibodies against Akt, phosphorylated Akt (Ser 473) and
phosphorylated GSK3b (Cell Signaling Technologies,
Beverly, MA, #9272, #9271 and #9336, respectively) were
diluted 1:750. Phosphorylated p70S6K (Cell Signaling Tech-
nologies, #9205) was used at a 1:250 dilution. b1D Integrin
(Temecula California; International, MAB1900) was diluted
1:100. Primary antibodies against proteins in the DGC and
UGC and their respective concentrations include dystrophin
(Vector Laboratories, Burlingame, CA, USA; VP-D507,
1:2), utrophin (University of Iowa, Hybridoma Facility;
MANCHO3, 1:200), a-DG (Upstate Cell Signaling Solutions,
Lake Placid, NY, USA; IIH6, 1:700), b-DG (University of
Iowa, Hybridoma Facility; MANDAG2, 1:10), a-SG (Vector
Laboratories; VP-A105, 1:20), b-SG (Vector Laboratories;
VP-B206, 1:100), g-SG (Vector Laboratories; VP-G803,
1:200) and SSPN [Rabbit 3 (described previously in 32),
1:50]. a7 Integrin antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA; L-17) was diluted 1:100 and a5 integrin
(Abcam, Cambridge, UK; ab55988) was diluted 1:50. Anti-
dysferlin antibody (Abcam; ab15108) was diluted 1:600.
Goat polyclonal antibodies were detected using horseradish
peroxidase-conjugated anti-goat IgG (Santa Cruz Biotechnol-
ogy, Inc.; SC-2033). Rabbit polyclonal antibodies were
detected using horseradish peroxidase-conjugated anti-rabbit
IgG (Amersham Pharmacia Biotech, Piscataway, NJ,
USA, #NA934). Mouse monoclonal primary antibodies
were detected by incubating with horseradish peroxidase-
conjugated anti-mouse IgG or IgM (Amersham Pharmacia
Biotech, 1:3000; Roche Applied Science, Indianapolis, IN,
USA; 1:1000, respectively) for 1 h. Immunoblots were devel-
oped using enhanced chemiluminescence with SuperSignal
West Pico Chemiluminescent Substrate (Pierce, # 34080).
Histology
Hematoxylin and eosin (H&E) staining was used for visualiza-
tion of ﬁbrosis, central nucleation and cross-sectional ﬁber
area as previously described (11). Transverse quadriceps sec-
tions were left at RT for 15 min prior to staining. Brieﬂy,
muscle sections were incubated with hematoxylin for 3 min,
washed with water for 1 min, incubated with eosin for
3 min, dehydrated in solutions of 70, 80, 90 and 100%
ethanol and then incubated in xylene for a total of 10 min.
Stained sections were mounted with permount. All supplies
for the H&E staining were purchased from Fisher Scientiﬁc
(Fairlawn, NJ, USA). Centrally nucleated ﬁbers and cross-
sectional ﬁber area were measured from digitized images cap-
tured under identical conditions with an Axioplan 2 ﬂuor-
escent microscope (Carl Zeiss Inc., Thornwood, NY, USA)
and Axiovision 4.5 software (Carl Zeiss Inc.). Central nuclea-
tion was quantiﬁed as a percentage of centrally nucleated
ﬁbers over the total number of ﬁbers in an entire transverse
quadriceps section. CSA of ﬁber diameters was calculated
using the outline spline function on the Axiovision 4.5 soft-
ware. For adult studies, DOX treatment was started at the
age of 10 weeks.
Evan’s blue tracer assay
To assess sarcolemmal permeability, 6-week-old mice were
intraperitoneally injected (50 ml per 10 g of body weight)
with sterilized EBD (10 mg/ml in sterile 10 mM phosphate
buffer, 150 mM NaCl, pH 7.4). Twenty-four hours post-
injection, muscles were excised and frozen in liquid nitrogen-
cooled isopentane. Transverse quadriceps cryosections (8 mm)
were prepared using a CM 3050S cryostat (Leica Microsys-
tems, Bannockburn, IL, USA). Sections were incubated with
ice-cold acetone, washed with PBS and blocked for 1 h at
RT with 3% BSA diluted in PBS. For sarcolemmal visualiza-
tion of EBD inﬁltrated ﬁbers, sections were incubated at 48C
for 18 h with an antibody to laminin (Sigma, St Louis, MO,
USA; L 9393) diluted at 1:25 in 1% BSA in PBS. Sections
were incubated at RT for 1 h with biotinylated anti-rabbit anti-
body (Vector Laboratories; BA-1000, 1:250) and then with
ﬂuorescein avidin D (Vector Laboratories; A-2001, 1:250).
Sections were mounted in VectaShield (Vector Laboratories;
H-1000) and imaged using the Axioplan 2 ﬂuorescent
microscope with green and blue excitation ﬁlters and the Axio-
vision 4.5 software (Carl Zeiss Inc.). Images were merged
using ImageJ software (available on http://rsbweb.nih.gov/ij/).
Quantiﬁcation of sarcolemmal integrity was quantiﬁed as a
percentage of EBD-positive ﬁbers over the total number of
ﬁbers counted in an entire transverse quadriceps section. Data
represented is the average percentage of EBD-positive ﬁbers
in both quadriceps of each animal.
Immunoﬂuorescence
Transverse sections were prepared from quadriceps muscles as
described earlier. All sections, except for those used for detect-
ing a-DG and SSPN, were acclimated to RT for 15 min and
then blocked with 3% BSA diluted in PBS for 30 min. The
Vectorw M.O.M.TM Immunodetection Kit (Vector Labora-
tories) was then used on these sections following manufac-
turer’s instructions. Primary antibodies diluted in M.O.M.
diluent were incubated at 48C for 18 h against their respective
proteins as follows: dystrophin (University of Iowa,
Hybridoma Facility; MANDYS1, 1:30), utrophin (Vector
Laboratories; VP-U579, 1:5), b1D integrin (Chemicon Inter-
national; MAB1900, 1:25), b-DG (Vector; VP-B205 1:15),
a-SG (Vector Laboratories; VP-A105, 1:30), b-SG (Vector
Laboratories; VP-B206, 1:30), g-SG (Vector Laboratories;
VP-G803, 1:15). Afterwards, the sections were incubated
with biotinylated anti-mouse antibody (1:250) provided in
the M.O.M. kit and then with ﬂuorescein avidin D (Vector
Laboratories; A-2001, 1:250). Sections used for detecting
a-DG and SSPN were blocked in 3% BSA diluted in PBS fol-
lowed by primary antibody incubations at 48C for 18 h as
follows: a-DG (Upstate Cell Signaling Solutions; VIA4-1,
1:20) and SSPN (Rabbit 3, 1:5). These primary antibodies
were detected by incubating for 1 h with FITC-conjugated
anti-mouse secondary antibody or with FITC-conjugated anti-
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Grove, PA; each, 1:500) for a-DG and SSPN, respectively.
Sections were mounted in VectaShield (Vector Laboratories).
Images were obtained using the Axioplan 2 ﬂuorescent micro-
scope and Axiovision 4.5 software (Carl Zeiss Inc.).
Statistical analyses
Central nucleation, EBD and quadriceps mass data were rep-
resented as means+SEM. The mean for each variable is cal-
culated as means of the average between the values from the
left and right quadriceps of each animal. A two-way
ANOVA followed by Fisher’s protected least signiﬁcant
difference (Fisher’s PLSD) method and the Kruskal–Wallis
nonparametric test was used for statistical analysis (Origin
7.0 Software; OriginLab Corporation; Northampton, MA).
Values were considered signiﬁcant when P , 0.05. For EBD
analysis, the Student’s t-test with Bonferroni adjustment to
signiﬁcance at P , 0.025 was used. Decreases in EBD ﬁbers
in WT DTG relative to WT STG mice could not be observed
because levels of EBD-positive ﬁbers were already near zero.
Because of this, the two-way ANOVA was not sufﬁcient in
assessing the decrease in EBD-positive ﬁbers seen in the
mdx mice.
Quantitative real-time PCR
Total RNA from whole skeletal muscle was prepared by
QIAGEN RNeasy kit using manufacturer protocols. cDNA
was produced using the ThermoScript RT–PCR System (Invi-
trogen). Real-time PCR was performed as described pre-
viously (18). Transcript levels were determined relative to
the signal from 36B4 and normalized to the mean value of
samples from WT STG control mice. Primer sequences for
each gene are as follows: utrophin (forward, 50-GTTTGAG
GTGCTTCCTCAGC-30; reverse, 50-GCGCTA TCTGGTAG
CTGTCC-30); gene 36B4 (forward, 50-GCTCC AAGCAGAT
GCAGCA-30; reverse, 50-CCGGATGTGAGGC AGCAG-30);
b-DG (forward, 50-CTGGAAGAACCAGCTT GAGG-30; rev-
erse, 50-AAATCCGTTGGAATGCTCAC-30); g-SG (forward,
50-TGAAACTGTGGGTTTGACCA-30; reverse, 50-GGTACA
GCTTCCCATCAGGA-30); dysferlin (forward, 50-AACACT
GGGTCCCTGTTGAG-30; reverse, 50-GCCTCTTCAGTGCT
TCCATC-30); MyoD (forward, 50-AGCACGCACACTTCCC
TACT-30; reverse, 50-TCTCGAAG GCCTCATTCACT-30);
integrin a7 (forward, 50-CTCTGC GTTCCTCAACATCA-30;
reverse, 50-TGTGCTAGGCTCCA CCTTCT-30).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We thank Dr M. Song and J.L. Marshall (UCLA) for technical
assistance.
Conﬂict of Interest statement. None declared.
FUNDING
A.K.P. and C.K. were supported by the Molecular, Cellular
and Integrative Physiology pre-doctoral training fellowship
(NIH: T32 GM65823). A.K.P. was also supported by the
Edith Hyde Fellowship, the Ursula Mandel Fellowship, and
the Harold and Lillian Kraus American Heart Pre-doctoral
Fellowship and Training in Cardiovascular Physiology and
Pharmacology Training Grant (5T32HL007444-27). N.O.
was supported by an American Heart Association grant.
K.W. was supported by National Institutes of Health (grant
HL81587). R.H.C. was supported by the NIH (AR48179-01)
and the Muscular Dystrophy Association (MDA3704).
REFERENCES
1. Hoffman, E.P., Brown, R.H. and Kunkel, L.M. (1987) Dystrophin: the
protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919–
928.
2. Ohlendieck, K. and Campbell, K.P. (1991) Dystrophin: the protein
product of the Duchenne muscular dystrophy locus. J. Cell Biol., 115,
1685–1694.
3. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G. and Campbell,
K.P. (1990) Deﬁciency of a glycoprotein component of the dystrophin
complex in dystrophic muscle. Nature, 345, 315–319.
4. Durbeej, M. and Campbell, K.P. (2002) Muscular dystrophies involving
the dystrophin-glycoprotein complex: an overview of current mouse
models. Curr. Opin. Genet. Dev., 12, 349–361.
5. Heydemann, A. and McNally, E.M. (2007) Consequences of disrupting
the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy.
Trends Cardiovasc. Med., 17, 55–59.
6. Campbell, K.P. and Kahl, S.D. (1989) Association of dystrophin and an
integral membrane glycoprotein. Nature, 338, 259–262.
7. Ervasti, J.M. and Campbell, K.P. (1991) Membrane organization of the
dystrophin-glycoprotein complex. Cell, 66, 1121–1131.
8. Ervasti, J.M., Kahl, S.D. and Campbell, K.P. (1991) Puriﬁcation of
dystrophin from skeletal muscle. J. Biol. Chem., 266, 9161–9165.
9. Ervasti, J.M. and Campbell, K.P. (1993) A role for the dystrophin–
glycoprotein complex as a transmembrane linker between laminin and
actin. J. Cell Biol., 122, 809–823.
10. Yoshida, M. and Ozawa, E. (1990) Glycoprotein complex anchoring
dystrophin to sarcolemma. J. Biochem., 108, 748–752.
11. Peter, A.K. and Crosbie, R.H. (2006) Hypertrophic response of Duchenne
and limb-girdle muscular dystrophies is associated with activation of Akt
pathway. Exp. Cell Res., 312, 2580–2591.
12. Dogra, C., Changotra, H., Wergedal, J.E. and Kumar, A. (2006)
Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear
factor-kappa B signaling pathways in dystrophin-deﬁcient skeletal muscle
in response to mechanical stretch. J. Cell Physiol., 208, 575–585.
13. Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt,
T.N., Yancopoulos, G.D. and Glass, D.J. (2001) Mediation of
IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and
PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol., 3, 1009–1013.
14. Takahashi, A., Kureishi, Y., Yang, J., Luo, Z., Guo, K., Mukhopadhyay,
D., Ivashchenko, Y., Branellec, D. and Walsh, K. (2002) Myogenic Akt
signaling regulates blood vessel recruitment during myoﬁber growth. Mol.
Cell Biol., 22, 4803–4814.
15. Bodine, S.C., Stitt, T.N., Gonzalez, M., Kline, W.O., Stover, G.L.,
Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J.C., Glass, D.J.
and Yancopoulos, G.D. (2001) Akt/mTOR pathway is a crucial regulator
of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.
Nat. Cell Biol., 3, 1014–1019.
16. Barton, E.R., Morris, L., Musaro, A., Rosenthal, N. and Sweeney, H.L.
(2002) Muscle-speciﬁc expression of insulin-like growth factor I counters
muscle decline in mdx mice. J. Cell Biol., 157, 137–148.
17. Pallafacchina, G., Calabria, E., Serrano, A.L., Kalhovde, J.M. and
Schiafﬁno, S. (2002) A protein kinase B-dependent and
rapamycin-sensitive pathway controls skeletal muscle growth but not ﬁber
type speciﬁcation. Proc. Natl. Acad. Sci. USA, 99, 9213–9218.
326 Human Molecular Genetics, 2009, Vol. 18, No. 218. Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J.,
Hamilton, J.A., Ouchi, N., LeBrasseur, N.K. and Walsh, K. (2008) Fast/
Glycolytic muscle ﬁber growth reduces fat mass and improves metabolic
parameters in obese mice. Cell Metab., 7, 159–172.
19. Kandarian, S.C. and Jackman, R.W. (2006) Intracellular signaling during
skeletal muscle atrophy. Muscle Nerve, 33, 155–165.
20. Neri, L.M., Borgatti, P., Capitani, S. and Martelli, A.M. (2002) The
nuclear phosphoinositide 3-kinase/AKT pathway: a new second
messenger system. Biochim. Biophys. Acta, 1584, 73–80.
21. Tinsley, J., Deconinck, N., Risher, R., Kahn, D., Phelps, S., Gillis, J.M.
and Davies, K. (1998) Expression of full-length utrophin prevents
muscular dystrophy in mdx mice. Nat. Med., 4, 1441–1444.
22. Tinsley, J.M., Potter, A.C., Phelps, S.R., Fisher, R., Trickett, J.I. and
Davies, K.E. (1996) Amelioration of the dystrophic phenotype of mdx
mice using a truncated utrophin transgene. Nature, 384, 349–353.
23. McArdle, A., Edwards, R.H. and Jackson, M.J. (1994) Time course of
changes in plasma membrane permeability in the dystrophin-deﬁcient
mdx mouse. Muscle Nerve, 17, 1378–1384.
24. Rosenberg, M.I., Georges, S.A., Asawachaicharn, A., Analau, E. and
Tapscott, S.J. (2006) MyoD inhibits Fstl1 and Utrn expression by inducing
transcription of miR-206. J. Cell Biol., 175, 77–85.
25. Cassano, M., Biressi, S., Finan, A., Benedetti, L., Omes, C., Boratto, R.,
Martin, F., Allegretti, M., Broccoli, V., Cusella De Angelis, G. et al.
(2008) Magic-factor 1, a partial agonist of Met, induces muscle
hypertrophy by protecting myogenic progenitors from apoptosis. PLoS
ONE, 3, e3223.
26. Hodges, B.L., Hayashi, Y.K., Nonaka, I., Wang, W., Arahata, K. and
Kaufman, S.J. (1997) Altered expression of the alpha7beta1 integrin
in human and murine muscular dystrophies. J. Cell Sci., 110,
2873–2881.
27. Bansal, D., Miyake, K., Vogel, S.S., Groh, S., Chen, C.C., Williamson,
R., McNeil, P.L. and Campbell, K.P. (2003) Defective membrane
repair in dysferlin-deﬁcient muscular dystrophy. Nature, 423,
168–172.
28. Burkin, D.J., Wallace, G.Q., Milner, D.J., Chaney, E.J., Mulligan, J.A. and
Kaufman, S.J. (2005) Transgenic expression of falphag7fbetag1 integrin
maintains muscle integrity, increases regenerative capacity, promotes
hypertrophy, and reduces cardiomyopathy in dystrophic mice.
Am. J. Pathol., 166, 253–263.
29. Wilson, E.M. and Rotwein, P. (2007) Selective control of skeletal muscle
differentiation by Akt1. J. Biol. Chem., 282, 5106–5110.
30. Tapscott, S.J. (2005) The circuitry of a master switch: Myod and the
regulation of skeletal muscle gene transcription. Development, 132,
2685–2695.
31. Rooney, J.E., Welser, J.V., Dechert, M.A., Flintoff-Dye, N.L.,
Kaufman, S.J. and Burkin, D.J. (2006) Severe muscular dystrophy
in mice that lack dystrophin and alpha7 integrin. J. Cell Sci., 119,
2185–2195.
32. Miller, G., Peter, A.K., Espinoza, E., Heighway, J. and Crosbie, R.H.
(2006) Over-expression of Microspan, a novel component of the
sarcoplasmic reticulum, causes severe muscle pathology with triad
abnormalities. J. Muscle Res. Cell Motil., 27, 545–558.
Human Molecular Genetics, 2009, Vol. 18, No. 2 327